Investments
80Portfolio Exits
40Funds
2About Logos Capital
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Want to inform investors similar to Logos Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Logos Capital News
Oct 13, 2022
Odyssey Therapeutics, a Boston, MA-based biotechnology company, raised $168M in Series B funding. The round was led by General Catalyst, with participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases. Gary D. Glick, Ph.D., Founder and Chief Executive Officer, Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. In addition, Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design; a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products; and a functional genomics platform for novel target discovery. FinSMEs 13/10/2022
Logos Capital Investments
80 Investments
Logos Capital has made 80 investments. Their latest investment was in Entact Bio as part of their Series A on December 12, 2022.
Logos Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/6/2022 | Series A | Entact Bio | $81M | Yes | 11 | |
10/13/2022 | Series B | Odyssey Therapeutics | $168M | No | Alexandria Venture Investments, Catalio Capital Management, Colt Ventures, Creacion Ventures, Fidelity Investments, Foresite Capital, General Catalyst, GreatPoint Ventures, HBM Healthcare Investments, Logos Capital, OrbiMed Advisors, SR One, SVB Securities, T. Rowe Price, Undisclosed Investors, Walleye Capital, and Woodline Partners | 20 |
10/10/2022 | PIPE | Immunic Therapeutics | $60M | Yes | 10 | |
6/13/2022 | Series B | |||||
2/17/2022 | Series E |
Date | 12/6/2022 | 10/13/2022 | 10/10/2022 | 6/13/2022 | 2/17/2022 |
|---|---|---|---|---|---|
Round | Series A | Series B | PIPE | Series B | Series E |
Company | Entact Bio | Odyssey Therapeutics | Immunic Therapeutics | ||
Amount | $81M | $168M | $60M | ||
New? | Yes | No | Yes | ||
Co-Investors | Alexandria Venture Investments, Catalio Capital Management, Colt Ventures, Creacion Ventures, Fidelity Investments, Foresite Capital, General Catalyst, GreatPoint Ventures, HBM Healthcare Investments, Logos Capital, OrbiMed Advisors, SR One, SVB Securities, T. Rowe Price, Undisclosed Investors, Walleye Capital, and Woodline Partners | ||||
Sources | 11 | 20 | 10 |
Logos Capital Portfolio Exits
40 Portfolio Exits
Logos Capital has 40 portfolio exits. Their latest portfolio exit was Enliven Therapeutics on February 23, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
2/23/2023 | Reverse Merger | 4 | |||
5/31/2022 | Acquired | 6 | |||
1/7/2022 | IPO | Public | 7 | ||
Date | 2/23/2023 | 5/31/2022 | 1/7/2022 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 6 | 7 |
Logos Capital Fund History
2 Fund Histories
Logos Capital has 2 funds, including Logos Opportunities Fund I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
9/10/2019 | Logos Opportunities Fund I | Late-Stage Venture Capital | Open | $6M | 1 |
Logos Opportunities Fund II |
Closing Date | 9/10/2019 | |
|---|---|---|
Fund | Logos Opportunities Fund I | Logos Opportunities Fund II |
Fund Type | Late-Stage Venture Capital | |
Status | Open | |
Amount | $6M | |
Sources | 1 |
Logos Capital Team
4 Team Members
Logos Capital has 4 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Graham Walmsley | Founder | Current | |
Name | Graham Walmsley | |||
|---|---|---|---|---|
Work History | ||||
Title | Founder | |||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.